Cargando…

Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients

OBJECTIVE: To investigate the association between the recurrence score (RS) obtained by Oncotype DX 21-gene test and long non-coding RNA (lncRNA) MALAT1 expression in early and estrogen receptor-positive (ER(+)) breast cancer. MATERIALS AND METHODS: The Oncotype DX 21-gene test and MALAT1 expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Zhen, Qin, Qinghong, Xia, Longjie, Lian, Bin, Tan, Qixing, Yu, Yinghua, Mo, Qinguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837574/ https://www.ncbi.nlm.nih.gov/pubmed/33519238 http://dx.doi.org/10.2147/CMAR.S276795

Ejemplares similares

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
por: Emmadi, Rajyasree, et al.
Publicado: (2015)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
por: Fried, Georgeta, et al.
Publicado: (2014)

Comparison of the Nottingham Prognostic Index and OncotypeDX© recurrence score in predicting outcome in estrogen receptor positive breast cancer
por: Kerin, Eoin P., et al.
Publicado: (2022)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
por: Guth, Amber A., et al.
Publicado: (2013)

Postoperative outcomes of breast reconstruction after mastectomy: A retrospective study
por: Qin, Qinghong, et al.
Publicado: (2018)

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
por: Malo, Teri L., et al.
Publicado: (2012)

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
por: Chen, Rui, et al.
Publicado: (2021)

Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX
por: Basavanhally, Ajay, et al.
Publicado: (2012)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Impact of Primary Site Surgery on Survival of Patients with de novo Stage IV Breast Cancer
por: Huang, Zhen, et al.
Publicado: (2021)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
por: Zhu, Xiaofu, et al.
Publicado: (2021)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
por: Iles, Kathleen, et al.
Publicado: (2022)

The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting
por: Choi, Joseph Do Woong, et al.
Publicado: (2022)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2023)

Combination of (125)I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study
por: Tan, Qixing, et al.
Publicado: (2016)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
por: Malam, Yogeshkumar, et al.
Publicado: (2021)

A Radio-genomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores
por: Wan, Tao, et al.
Publicado: (2016)

The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
por: Rizki, Hirah, et al.
Publicado: (2020)

GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients
por: Zhang, Guochun, et al.
Publicado: (2019)

Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
por: Mislick, Kimberly, et al.
Publicado: (2014)

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry
por: Baehner, FL, et al.
Publicado: (2009)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h27u0maj4vsrfu3p3ak40gabo0